Mr. Aliski has served as a member of the Ultragenyx Board since January 2011. He currently serves on the board of directors of Applied Genetic Technologies Corporation, and on the board of directors of X4 Pharmaceuticals, Inc.. He has served as a commercial consultant for early-stage orphan disease companies, including Audenties Therapeutics, Inc. from September 2018 to March 2019, Ra Pharmaceuticals, Inc., from October 2016 to March 2017, Clementia Pharmaceuticals, Inc., from December 2015 to January 2017 and May 2018 to present, OxThera, from January 2015 through April 2015, Prosensa during 2014, Adimab LLC from November 2013 until December 2013, NPS Pharmaceuticals from April 2013 through December 2014, Fidelity Biosciences from August 2012 until December 2012, and Enobia Pharma from September 2011 until March 2012. Before that, Mr. Aliski served as Senior Vice President and Chief Commercial Officer of FoldRx Pharmaceuticals, a rare disease company that is now a wholly-owned subsidiary of Pfizer Inc., from June 2009 until March 2011, as Director of Simon Kucher Partners, a global consulting firm, from January 2008 until June 2009, and as General Manager of BioMarin Europe at BioMarin Pharmaceuticals from December 2005 until January 2008.
Mr. Aliski received a B.S. in economics and a Master of Social Planning degree from Boston College and an M.P.A. from the Kennedy School of Government at Harvard University. He has extensive leadership and management experience in the life sciences industry and is a member of various Boards of Directors.